SUNPHARMA

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA

BSE: 524715

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,906.80+35.8 (+1.91%)

3 Jul, 9:59 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

95.7 / 100

Value Score

32.3 / 100

Price Momentum Score

83.0 / 100

QVM Score

88.9 / 100

Key Metrics

Market Cap

4,48,916 Cr

P/E (TTM)

39.11

P/B

5.37

P/S (TTM)

7.68

EV/EBITDA

25.44

CAPE (5Y)

51.80

ROE (TTM)

14.74

ROCE (TTM)

16.59

ROA (TTM)

11.43

Avg 3Y ROE

15.61

Earnings 3Y CAGR

9.36

Sales 3Y CAGR

10.03

Sales 5Y CAGR

11.78

Debt/Equity

0.06

Consensus TP

2070.00

Strong Buy %

30.30

Promoter Holding

54.48

Pledged %

1.42

Stock Analysis

Fundamental analysis overview of Sun Pharmaceutical Industries Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 83.0 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

83.0 / 100

High and stable operating margin

The company reported strong operating margin of 23.18% for 12-month ended 31 Mar 2026 and operating margin declined marginally by -75 bps from 1 year ago

What is Operating profit margin?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.06 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.03 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 39.11 indicates that the stock is expensive on a standalone basis and is at a 29.25% premium to industry median P/E

What is P/E Ratio?

Median: 30.26

Value 39.11

-215.443183

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -1.46% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of 1.42% for 12-month ended 31 Mar 2026 and the growth was 6.7 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.88%

What is Dividend yield?

Neutral

Moderate and stable ROE

The company reported moderate ROE of 14.74% for 12-month ended 31 Mar 2026 and ROE declined marginally by -135 bps from 1 year ago

What is ROE (FY)?

Moderate revenue growth and in line with median growth of industry

The company delivered moderate revenue growth of 11.19% for 12-month ended 31 Mar 2026 and the growth was 0.05 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.24

Value 11.19

-82.35114662

Company's earnings are of moderate quality

Earnings quality score of 57.3 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

57.3 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Sun Pharmaceutical Industries Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Sun Pharmaceutical Industries Ltd. Shareholding Pattern

Quarterly breakdown of Sun Pharmaceutical Industries Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	54.69	54.69	54.69	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48
Indian Promoter	54.69	54.69	54.69	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	32.37	32.81	32.83	33.03	33.29	33.47	33.80	33.99	34.46	34.61	35.63	36.01	36.12	36.23	36.44	36.59	36.54	36.51	36.62	36.59	36.66	36.75	36.78	36.93	37.04
Mutual Funds / UTI	10.94	10.52	10.71	11.13	11.93	12.03	11.72	11.80	11.63	11.84	12.22	12.46	12.91	13.16	13.07	12.93	12.21	12.78	12.11	12.24	12.21	12.63	12.41	12.09	11.96
FI/Bank/Insurance	8.54	9.38	9.52	9.67	9.65	9.91	9.95	9.14	8.31	7.74	6.53	5.69	5.23	5.27	5.16	5.09	5.12	5.00	5.00	4.79	4.95	5.15	6.04	6.66	6.93
Govt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	12.81	12.70	12.38	12.19	11.67	11.50	12.07	13.00	14.44	14.95	15.99	16.87	16.88	16.48	16.78	17.08	17.72	17.23	18.01	18.05	17.96	17.26	16.55	16.12	15.93
Other Institutions	0.08	0.21	0.23	0.04	0.04	0.04	0.05	0.06	0.08	0.09	0.89	0.99	1.10	1.31	1.43	1.51	1.49	1.50	1.48	1.51	1.53	1.71	1.78	2.07	2.22
Non-Institution	12.94	12.50	12.48	12.49	12.23	12.05	11.72	11.53	11.06	10.91	9.88	9.51	9.41	9.29	9.07	8.92	8.97	9.02	8.90	8.93	8.87	8.77	8.73	8.58	8.48
Bodies Corporate	3.63	3.51	3.40	3.31	3.27	3.22	3.19	3.02	2.94	2.90	2.31	2.31	2.28	2.25	2.15	2.14	2.09	2.09	2.10	2.10	2.08	2.07	2.05	2.03	2.02
Others (incl. Retail) No. of shareholders	9.31 6,27,434	8.99 6,49,529	9.08 6,84,731	9.18 6,48,267	8.96 7,05,358	8.83 7,53,731	8.53 6,72,428	8.51 6,77,276	8.12 6,58,824	8.01 6,43,762	7.57 6,40,165	7.20 6,28,961	7.13 6,21,913	7.04 6,21,219	6.92 6,13,259	6.78 6,09,281	6.88 6,27,631	6.93 6,69,352	6.80 6,53,386	6.83 6,85,515	6.79 7,00,820	6.70 7,19,842	6.68 7,39,891	6.55 7,07,145	6.46 6,87,393

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Pharma	21.43%	1 / 20
2	Nifty Healthcare	18.37%	1 / 20
3	Nifty 100 Low Volatility 30	3.41%	15 / 30
4	Nifty Alpha Low Vol 30	3.32%	18 / 30
5	Nifty 50 Equal Weight	1.9%	34 / 50
6	Nifty 50	1.76%	15 / 50
7	Nifty 100	1.44%	14 / 100
8	Nifty 500	0.99%	15 / 499
9	Nifty Total Market	0.95%	15 / 749
10	Nifty 100 Equal Weight	0.93%	70 / 100

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Sun Pharmaceutical Industries Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Sailesh T. Desai Director	March-2023	Market Sale (Disposal) 20th Mar 2023	0.10 %	₹ 965.74	4.00 k	₹ 38.63 lac
Sailesh T. Desai Director	December-2022	Market Sale (Disposal) 23rd Dec 2022	0.10 %	₹ 1,028.14	5.00 k	₹ 51.41 lac
Sailesh T. Desai Director	December-2022	Market Sale (Disposal) 23rd Dec 2022	0.10 %	₹ 1,021.60	2.00 k	₹ 20.43 lac
Sailesh T. Desai Director	December-2022	Market Sale (Disposal) 23rd Dec 2022	0.10 %	₹ 1,025.00	2.00 k	₹ 20.50 lac
Nilesh Gandhi Designated Person	December-2022	Market Sale (Disposal) 8th Dec 2022	0.00 %	₹ 1,028.54	2.00 k	₹ 20.57 lac
Priti Gandhi Immediate Relative	December-2022	Market Sale (Disposal) 8th Dec 2022	0.00 %	₹ 1,030.00	3.00 k	₹ 30.90 lac
Desai Associates Partnership firm in which Ms. Meera Desai wife of Mr. Sailesh T. Desai Whole-time Director is one of the partners Other	December-2022	Market Sale (Disposal) 2nd Dec 2022	0.01 %	₹ 1,055.00	1.00 k	₹ 10.55 lac
Sailesh T. Desai Director	December-2022	Market Sale (Disposal) 1st Dec 2022	0.09 %	₹ 1,047.63	6.00 k	₹ 62.86 lac
Desai Associates Partnership firm in which Meera Desai wife of Sailesh T. Desai WTD is a Partner Other	December-2022	Market Sale (Disposal) 1st Dec 2022	0.01 %	₹ 1,049.00	1.00 k	₹ 10.49 lac
Sailesh T. Desai Director	November-2022	Market Sale (Disposal) 25th Nov 2022	0.09 %	₹ 1,030.45	10.00 k	₹ 1.03 cr

…

Corporate Actions

History of Sun Pharmaceutical Industries Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 5/share
Record date: 7th Jul 2026Ex-date: 7th Jul 2026
Announced on: 22nd May 2026
Dividend₹ 11/share
Record date: 5th Feb 2026Ex-date: 5th Feb 2026
Announced on: 20th Jan 2026
Dividend₹ 5.50/share
Record date: 7th Jul 2025Ex-date: 7th Jul 2025
Announced on: 22nd May 2025
Dividend₹ 10.50/share
Record date: 6th Feb 2025Ex-date: 6th Feb 2025
Announced on: 16th Jan 2025
Dividend₹ 5/share
Record date: 12th Jul 2024Ex-date: 12th Jul 2024
Announced on: 22nd May 2024

Company Profile

Overview of Sun Pharmaceutical Industries Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Companys global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among other...

Key personnel

Ms. Jayashree Satagopan

Chief Financial Officer

Mr. Anoop Anjanikumar Deshpande

Compliance Officer, Company Secretary

Mr. Kirti Ganorkar

Managing Director

Dr. Abhishek Sharma

Investor Relations Officer

Dr. Abhishek Sharma

Investor Relations Officer

Mr. Dilip Shantilal ShanghviD

Executive Chairman of the Board

Mr. Aalok Dilip ShanghviD

Whole-time Director and Chief Operating Officer

Ms. Vidhi Dilip ShanghviD

Whole-Time Director

View all

Incorporated on

01 Mar 1993

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

01 Jan 1994

Free Float

1,06,50,37,062

Website

https://sunpharma.com/

Phone no.

+912243244324

Address

Sun House,, CTS No. 201 B/1,, Western Express Highway,Goregaon (E),, MUMBAI, 400063, India

Frequently Asked Questions

What is the current share price of Sun Pharmaceutical Industries Ltd.?

The current share price of Sun Pharmaceutical Industries Ltd. is ₹ 1,906.80 as of 3 Jul 2026.

What is the market capitalisation of Sun Pharmaceutical Industries Ltd.?

The market capitalisation of Sun Pharmaceutical Industries Ltd. stands at ₹ 4,48,916.00 Cr.

What is the PE ratio of Sun Pharmaceutical Industries Ltd.?

The Price-to-Earnings (PE) ratio of Sun Pharmaceutical Industries Ltd. is 39.11 as of the latest trailing twelve months data.

What is the ROE and ROCE of Sun Pharmaceutical Industries Ltd.?

Sun Pharmaceutical Industries Ltd. has a Return on Equity (ROE) of 14.74% and a Return on Capital Employed (ROCE) of 16.59% as per the latest financial reports.

What is the 52-week high and low of Sun Pharmaceutical Industries Ltd.?

The 52-week high of Sun Pharmaceutical Industries Ltd. is - and the 52-week low is -.

What is the dividend yield of Sun Pharmaceutical Industries Ltd.?

The dividend yield of Sun Pharmaceutical Industries Ltd. is 0.88% based on the current market price.

What is the FII and DII holding in Sun Pharmaceutical Industries Ltd.?

Foreign Institutional Investors (FII) hold 15.93%, Domestic Institutional Investors (DII) hold 18.89% and retail/public investors hold 6.46% of Sun Pharmaceutical Industries Ltd. shares.

What sector does Sun Pharmaceutical Industries Ltd. belong to?

Sun Pharmaceutical Industries Ltd. operates in the Healthcare sector. 87.88% of analysts have a Buy or Strong Buy rating on Sun Pharmaceutical Industries Ltd. with a consensus target price of ₹ 2,070.00, implying 10.64% upside from current levels.

What is the beta of Sun Pharmaceutical Industries Ltd.?

The beta of Sun Pharmaceutical Industries Ltd. is 0.51, indicating its price volatility relative to the broader market. Over the past 1 year, Sun Pharmaceutical Industries Ltd. has delivered an absolute return of 12.60%.

What is the RSI of Sun Pharmaceutical Industries Ltd.?

The 14-day Relative Strength Index (RSI) of Sun Pharmaceutical Industries Ltd. is 62.44, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Sun Pharmaceutical Industries Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Sun Pharmaceutical Industries Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Company Profile

Holdings and Presence

Stock Analysis

Corporate Actions